Skip to main content

New drug combination boosts survival in advanced stomach and esophageal

Patients whose metastatic stomach or esophageal cancers were driven by a mutated HER2 gene had markedly improved response rates and survival when bevacizumab (Avastin) was added to a standard drug combination. Scientists at Dana-Farber Cancer Institute, who led the research, will report these findings at the annual meeting of the American Society of Clinical Oncology (ASCO) on Monday, June 1, 2015.
https://www.healthcanal.com/cancers/63521-new-drug-combination-boosts-survival-in-advanced-stomach-and-esophageal.html

Disclaimer: This information is for educational purposes only, It is not to diagnose or treat your disease. If you do use the information contained on this web site without the approval of a health professional, you are prescribing for yourself, which is your constitutional right, but the author(s) and webmaster assume no responsibility

© 2024 Esophageal Cancer Education Foundation- by domino